Povofortay infographic: povorcitinib EU approval for hidradenitis suppurativa, 42.3% HiSCR50 at week 12

Povofortay (povorcitinib), Incyte’s once-daily JAK1 inhibitor pill, was approved by the European Commission on 16 November 2026 for adults with active moderate to severe hidradenitis suppurativa (HS) who have not responded to, cannot tolerate, or cannot take an anti-TNF biologic. Incyte says it is the first once-daily oral treatment approved in the EU for HS, a painful chronic skin disease that affects about 1% of people worldwide. The approval rests on two Phase 3 trials, STOP-HS1 and STOP-HS2, of roughly 600 patients each; a US FDA decision is expected to support a launch in the first quarter of 2027.

Key takeaways on Povofortay

  • EU approval covers 45 mg and 75 mg tablets taken once a day, for adults with moderate to severe HS after anti-TNF therapy.
  • At week 12, about 40% to 42% of patients on povorcitinib reached the primary HiSCR50 response, versus about 29% on placebo.
  • With continued treatment, up to 71.4% reached HiSCR50 and up to 29% reached complete clearance of inflammatory lesions (HiSCR100) by week 54.
  • Common side effects were acne, colds and upper respiratory infections, mostly mild or moderate; no new safety signals appeared over 54 weeks.
  • The FDA is reviewing the US application; Incyte expects US approval and launch in Q1 2027. There is no approval in India yet.

Who the EU label covers

The indication is deliberately narrower than the trial population. Both STOP-HS studies enrolled adults with moderate to severe HS regardless of prior biologic use, but the European label limits Povofortay to people for whom an anti-TNF drug such as adalimumab has failed, been poorly tolerated, or is unsuitable. That positions the pill as a second-line option alongside the injectable IL-17 biologics, rather than as a first choice. Incyte’s announcement says post-anti-TNF patients in the trials responded better than placebo, but did not publish subgroup percentages.

STOP-HS1 and STOP-HS2 results at a glance

HiSCR50 means at least a 50% fall in the combined count of abscesses and inflammatory nodules, with no increase in abscesses or draining tunnels. Week 12 figures below come from Incyte’s March 2025 topline release.

Week 12 HiSCR5045 mg75 mgPlaceboGap vs placebo (by our calculation)
STOP-HS140.2%40.6%29.7%+10.5 to +10.9 points
STOP-HS242.3%42.3%28.6%+13.7 points

All four comparisons were statistically significant (p values from 0.003 to 0.024). The placebo response near 30% is typical of HS trials, where symptoms naturally wax and wane, and it is why the absolute gap looks modest. By our calculation, roughly one extra responder for every eight to ten patients treated at week 12. The longer-term picture is stronger: through week 54, up to 71.4% of patients reached HiSCR50, up to 57% reached HiSCR75, and up to 29% reached HiSCR100. Patient-reported improvements at week 54 included skin pain in 40.5% to 46.8% and fatigue in 49.0% to 58.0%. Those later figures come from open treatment periods without a placebo comparison, so they should not be read as direct efficacy versus placebo.

How a JAK1 pill works in HS

HS starts in hair follicles in skin folds such as the armpits, groin and under the breasts, where blocked follicles rupture and trigger deep, recurring inflammation. Several of the cytokines that drive that inflammation, including interferons and IL-6 family signals, pass their messages through the JAK/STAT pathway. Povorcitinib selectively blocks JAK1, damping several of these signals at once. The practical difference for patients is the route: current advanced HS therapies in Europe (adalimumab, secukinumab and bimekizumab) are injections, while Povofortay is a daily tablet.

Safety: what patients and doctors will weigh

In the trials, the most frequent side effects were acne, nasopharyngitis and upper respiratory tract infections, and most were mild or moderate. Incyte reports no new or unexpected safety signals across 54 weeks. The wider context is the JAK class: in 2023 the European Medicines Agency recommended that JAK inhibitors used for chronic inflammatory diseases be reserved, where possible, for patients without suitable alternatives if they are 65 or older, current or past long-term smokers, or at higher risk of heart problems, blood clots or cancer. How those class precautions are reflected in Povofortay’s product information should be checked in the official EU summary of product characteristics once published. As with all JAK inhibitors, infection screening before treatment is standard practice.

Market context

Oral options are a growth area in skin medicine. Acumen Research and Consulting valued the global dermatologicals market at USD 23.7 billion in 2022 and projects USD 64.7 billion by 2032, a compound annual growth rate of 10.7%, with prescription drugs holding the largest share and Europe forecast as the fastest-growing region. HS has been one of the more active corners of that market, with three biologics approved in Europe within a few years and now a first oral entrant.

India angle and what comes next

HS is under-diagnosed in India, as in many countries, and is often mistaken for recurrent boils, delaying specialist care by years. Povorcitinib has no CDSCO approval and Incyte has not announced an Indian filing, so Indian patients will continue to rely on existing options, including biologics and their biosimilars where available. The next milestones are the FDA decision, which Incyte expects to support a US launch in Q1 2027, and the national pricing and reimbursement decisions that determine real access across EU countries. For other recent EU decisions, see our coverage of Frehemgo’s EU approval and the Gazyva lupus CHMP opinion, or browse all drug approvals.

FAQ

What is Povofortay used for?

In the EU, Povofortay (povorcitinib) treats adults with active moderate to severe hidradenitis suppurativa who did not respond to, could not tolerate, or cannot use an anti-TNF therapy.

Is povorcitinib approved by the FDA?

Not yet. The FDA is reviewing Incyte’s application, and the company expects US approval and launch in the first quarter of 2027.

How well does povorcitinib work for HS?

About 40% to 42% of patients reached HiSCR50 at 12 weeks versus about 29% on placebo, and up to 71.4% reached it by week 54 with continued treatment.

Is Povofortay available in India?

No. It has not been approved by CDSCO and no Indian filing has been announced.

Sources: Incyte press releases (16 November 2026; 17 March 2025), European Medicines Agency. Market data: Acumen Research and Consulting, Dermatologicals Market report. Not medical advice; treatment decisions belong with a dermatologist. Last updated: 17 November 2026.

By Simone Lamb

Simone Lamb is the editor of Medgadget.in, covering healthcare technology, medical devices, and the latest developments in digital health.

Leave a Reply

Your email address will not be published. Required fields are marked *